Heiss W D, Reisner T, Reisner H, Havelec L, Kubicek F, Dietmann K
Wien Klin Wochenschr. 1976 Mar 5;88(5):171-4.
The effect of 0.25 mg ouabain on cerebral blood flow (CBF) was investigated in patients with and without cerebrovascular disease using the xenon clearance method. The 36 patients included in this study did not show any signs of heart failure. Ouabain increased the CBF and this effect was demonstrable 15, as well as 90 min. after administration. This effect was proven statistically using the t-test for a comparison of the values with spontaneous changes in a control group without medication. The perfusion of pathologically-supplied brain regions was altered in the same way as the hemispheric flow; changes in the distribution of blood in the way of a steal effect were not observed. The haemodynamic parameters do not indicate a primary cardiac effect. Hence, an influence of ouabain on cerebral vessels might be responsible. The present results support reported clinical experience with ouabain for the treatment of patients with cerebrosvascular disease.
采用氙清除法,在患有和未患有脑血管疾病的患者中研究了0.25毫克哇巴因对脑血流量(CBF)的影响。本研究纳入的36例患者未表现出任何心力衰竭迹象。哇巴因可增加CBF,给药后15分钟以及90分钟时均能证实这种作用。通过t检验对这些值与未用药对照组的自发变化进行比较,从统计学上证明了这种作用。病理供应脑区的灌注与半球血流量的变化方式相同;未观察到血液分布以盗血效应的方式发生变化。血流动力学参数未表明存在原发性心脏效应。因此,哇巴因对脑血管的影响可能是原因所在。目前的结果支持了报道的关于哇巴因治疗脑血管疾病患者的临床经验。